Celularity Inc
For the period ended Dec 31, 2023. Filed Jul 30, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Jul 30, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accounting Fees and Services
Our independent public accounting firm is Deloitte & Touche, LLP, Parsippany, NJ PCAOB Auditor ID 34.
Deloitte & Touche LLP has served as our independent registered public accounting firm since 2021 and has audited the financial statements of Legacy Celularity since 2018.
We incurred the following fees from Deloitte & Touche LLP, and its respective affiliates, or the Deloitte Entities, for the audit of the consolidated financial statements, and for fees billed for other services provided by the Deloitte Entities for the fiscal years ended December 31, 2023 and 2022:
| 2023 | 2022 | |
|---|---|---|
| Audit Fees(1) | $2,139,760 | $1,792,806 |
| Audit Related Fees | — | — |
| Tax Fees(2) | — | — |
| All Other Fees(3) | — | 2,021 |
| Total | $2,139,760 | $1,794,827 |
Includes fees associated with the annual audit of our financial statements, the reviews of our interim financial statements and the issuance of consent and comfort letters in connection with registration statements.
Includes fees billed for professional services relating to tax compliance, tax planning and tax advice.
Includes annual license fee for access to an accounting research software application.
Audit Committee Pre-Approval Policies
The audit committee of our Board is directly responsible for the appointment, retention and termination, and for determining the compensation, of our independent registered public accounting firm. The audit committee pre-approves all auditing services and the terms thereof and non-audit services (other than non-audit services prohibited under Section 10A(g) of the Exchange Act or the applicable rules of the SEC or the PCAOB), except that pre-approval is not required for the provision of non-audit services if the “de minimis” provisions of Section 10A(i)(1)(B) of the Exchange Act are satisfied. The audit committee may delegate to the chairperson of the Audit Committee the authority to grant pre-approvals for audit and non-audit services, provided such approvals are presented to the audit committee at its next scheduled meeting. All services provided by Deloitte & Touche LLP during fiscal year 2023 were pre-approved by the audit committee in accordance with the pre-approval policy described above.
Part IV
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.